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Background: In April 2019 SCAI published the first consensus document on patent foramen ovale (PFO) 
closure after cryptogenic stroke, driven by the positive results of CLOSE, REDUCE, and DEFENSE-PFO 
trials.1 Aim: To analyze referral and indication for PFO closure in our institution before and after April 
2019. 
Methods: We analyzed clinical characteristics, imaging data, referral information and follow-up data 
of patients that underwent PFO closure before and after the publication of 2019 consensus document. 
Results: From 2016 to 2020 a total of 26 patients underwent PFO closure (14 patients before, and 12 pa-
tients after the 2019 consensus paper). There were no significant differences in patient’s demographic 
and clinical characteristics. Patients in both groups were all referred by a neurologist after stroke/
TIA and underwent CT or MRI brain scan, 24-h ECG monitoring and TEE exam before the procedure. 
All patients treated after the 2019 consensus had subcortical lesions on CT or MRI. Only 1 patient in 
pre-consensus group with history of TIA had no imaging evidence of subcortical ischemia before the 
procedure. All patients had and at least 1 TEE high risk feature. There were more patients on direct oral 
anticoagulation drugs after stroke after the 2019 consensus. All patients were treated with Amplatzer 
device and received dual antiplatelet therapy for at least 3 months, with additional ASA continued in-
definitely in selected high-risk patients. There were no documented recurrent ischemic events or new 
onset atrial fibrillation within 1 year after PFO closure in both groups. 
Conclusion: There were no significant differences in referral and indications for PFO closure before and 
after the 2019 consensus. Very careful patient selection, in concordance with the consensus, relates to 
procedure safety and long-term outcomes. Neurologists remain the gatekeepers, whereas cardiologists 
plan and perform the procedure, and tailor postprocedural antithrombotic therapy. We observed an 
increase in annual volume after the consensus, most probably because of increased awareness after 
2018, and facilitation of the decision to perform PFO closure after cryptogenic stroke brought by the 
consensus document. 
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